Shin Teak Jun, Song Cheryn, Jeong Chang Wook, Kwak Cheol, Seo Seongil, Kang Minyong, Chung Jinsoo, Hong Sung-Hoo, Hwang Eu Chang, Park Jae Young, Lee Hakmin
Department of Urology, Keimyung University School of Medicine, Dongsan Hospital, Daegu, Republic of Korea.
Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
J Surg Oncol. 2021 Jan;123(1):204-213. doi: 10.1002/jso.26251. Epub 2020 Oct 12.
Metastatic renal cell carcinoma to the pancreas (PM-RCC) is infrequent; we sought to describe the characteristics of PM-RCC and analyze the outcome following treatment.
Data of 3107 mRCC patients treated between 1992 and 2007 from the Korean Renal Cancer Study Group database were obtained to identify 300 (9.7%) PM-RCC patients. Characteristics and survival were analyzed and compared to the rest of the mRCC, according to the timing of metastasis and surgical treatments received.
PM-RCC was younger at initial diagnosis (55.0 vs. 58.2 years), more frequently in women (30.3% vs. 22.3%), and metachronous (65.3% vs. 41.9%) with a longer disease-free period (82.0 vs. 33.0 months). Overall survival (OS) was significantly better in PM-RCC but pancreas metastasectomy was associated with improved OS only among metachronous PM-RCC. In the 132 metachronous PM-RCC with pancreas metastasectomy, median recurrence-free survival was 17.2 months and we found Heng risk group (hazard ratio [HR] = 2.384, 95% confidence interval [CI] = 1.213-4.684), younger age (HR = 0.965, 95% CI = 0.945-0.987), shorter interval to pancreas metastasis (HR = 0.993, 95% CI = 0.986-0.999), and Eastern Cooperative Oncology Group performance status to be predictive of early progression following pancreas metastasectomy.
Compared to the other mRCC, PM-RCC demonstrated a favorable prognosis. Pancreas metastasectomy was associated with prolonged survival in the metachronous PM-RCC with a long progression-free period.
胰腺转移性肾细胞癌（PM-RCC）并不常见；我们试图描述PM-RCC的特征并分析治疗后的结果。
从韩国肾癌研究组数据库中获取1992年至2007年间接受治疗的3107例转移性肾细胞癌（mRCC）患者的数据，以确定300例（9.7%）PM-RCC患者。根据转移时间和接受的手术治疗，分析并比较了PM-RCC患者与其余mRCC患者的特征及生存率。
PM-RCC患者初诊时年龄较轻（55.0岁对58.2岁），女性更为常见（30.3%对22.3%），多为异时性转移（65.3%对41.9%），无病生存期更长（82.0个月对33.0个月）。PM-RCC患者的总生存期（OS）明显更好，但仅在异时性PM-RCC患者中，胰腺转移瘤切除术与OS改善相关。在132例行胰腺转移瘤切除术的异时性PM-RCC患者中，无复发生存期的中位数为17.2个月，我们发现Heng风险组（风险比[HR]=2.384，95%置信区间[CI]=1.213-4.684）、年龄较小（HR=0.965，95%CI=0.945-0.987）、至胰腺转移的间隔时间较短（HR=0.993，95%CI=0.986-0.999）以及东部肿瘤协作组体能状态可预测胰腺转移瘤切除术后的早期进展。
与其他mRCC相比，PM-RCC显示出较好的预后。胰腺转移瘤切除术与无进展生存期长的异时性PM-RCC患者的生存期延长相关。
